Laura Schultze-Rhonhof, Julia Marzi, Daniel Alejandro Carvajal Berrio, Myriam Holl, Theresa Braun, Felix Schäfer-Ruoff, Jürgen Andress, Cornelia Bachmann, Markus Templin, Sara Y Brucker, Katja Schenke-Layland, Martin Weiss
In the context of multimodal treatments for abdominal cancer, including procedures such as cytoreductive surgery and intraperitoneal chemotherapy, recurrence rates remain high, and long-term survival benefits are uncertain due to post-operative complications. Notably, treatment-limiting side effects often arise from an uncontrolled activation of the immune system, particularly peritoneally localized macrophages, leading to massive cytokine secretion and phenotype changes. Exploring alternatives, an increasing number of studies investigated the potential of plasma-activated liquids (PAL) for adjuvant peritoneal cancer treatment, aiming to mitigate side effects, preserve healthy tissue, and reduce cytotoxicity towards non-cancer cells...
2024: Frontiers in Immunology